Skip to content

Evaluation anti-hyperlipidemia effect of Pistacia atlantica Desf. ssp. Kurdica versus placebo in diabetic patients

Evaluation anti-hyperlipidemia effect of Pistacia atlantica Desf. ssp. Kurdica versus placebo in diabetic patients: A triple blind randomized clinical trial

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201708109014N178
Enrollment
58
Registered
2017-08-13
Start date
2017-08-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia. Hyperlipidaemia, unspecified

Interventions

Intervention 1: Intervention group: Tablet Atorvastatin 40 mg once a day for 2 months plus capsule including dried powder of Pistacia Atlantica Kurdica 2 gr once a day for 2 months. Intervention 2: C
Treatment - Drugs
Intervention group: Tablet Atorvastatin 40 mg once a day for 2 months plus capsule including dried powder of Pistacia Atlantica Kurdica 2 gr once a day for 2 months.
Control group: Tablet Atorvastatin 40 mg once a day for 2 months plus capsule including starch 2 gr once a day for 2 months.

Sponsors

Vice-chancellor for Research and Technology, Hamadan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age of 18 to 65 years; hypercholesterolemia; HbA1C between 6 to 10. Exclusion criteria: Renal disease; Liver disorder; gastric problem; heart failure; brain disease; sensitivity to Pistacia Atlantica Kurdica; insulin usage; myopathy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Assessing serum cholesterol. Timepoint: before and 1 and 2 months after intervention. Method of measurement: through laboratory test.;Assessing blood sugar. Timepoint: before and 1 and 2 months after intervention. Method of measurement: through laboratory test.

Secondary

MeasureTime frame
Assessing side effects including nausea and vomiting. Timepoint: 1 and 2 months after intervention. Method of measurement: through history taking.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFaezeh Safari Majd

School of Pharmacy

f.safarimajd@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 17, 2026